MSL
NBIX icon

Mackay Shields LLC’s Neurocrine Biosciences NBIX Stock Holding History

Mackay Shields LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,755
Closed -$754K – 1100
2021
Q1 		$754K Hold
7,755
– – 0.01% 1084
2020
Q4 		$743K Sell
7,755
-16,857
-68% -$1.63M 0.01% 1157
2020
Q3 		$2.37M Sell
24,612
-8,437
-26% -$976K 0.02% 711
2020
Q2 		$4.03M Sell
33,049
-8,158
-20% -$902K 0.03% 474
2020
Q1 		$3.57M Buy
+41,207
New +$4.03M 0.03% 455
2019
Q1 		– Sell
-17,772
Closed -$1.27M – 1422
2018
Q4 		$1.27M Buy
+17,772
New +$1.7M 0.01% 854

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

Mackay Shields LLC's NBIX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 7,755 shares — an estimated $754K sold.

Mackay Shields LLC first reported a position in NBIX in Q4 2018 and held it in 6 quarters. The position peaked at $4.03M in Q2 2020. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 7,755 Neurocrine Biosciences shares in Q2 2021, an estimated $754K.
  • Mackay Shields LLC first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 6 quarters.
  • Mackay Shields LLC's Neurocrine Biosciences position peaked at $4.03M in Q2 2020.
  • 408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.